Completed PHASE1 INTERVENTIONAL 1-arm NCT01736436

APG101 in Myelodysplastic Syndrome (APG101 in MDS)

APG101 in Transfusion-Dependent Patients With Low or Intermediate Risk Myelodysplastic Syndrome

Sponsor: Apogenix GmbH

Interventions Blood drawings Bone marrow collection Treatment with APG101

Updated 6 times since 2017 Last updated: Aug 23, 2016 Started: Jan 31, 2013 Primary completion: Dec 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Myelodysplastic Syndrome and is currently completed. Apogenix GmbH leads this study, which shows 6 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Oct 2020 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Oct 2020 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Apogenix GmbH

Data source: Apogenix AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Heidelberg, Germany
• Mannheim, Germany